Spots Global Cancer Trial Database for parp inhibitors
Every month we try and update this database with for parp inhibitors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | NCT06161272 | Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ... | Fluzoparib Fluzoparib+Apat... | 18 Years - 75 Years | Guangxi Medical University | |
| Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB) | NCT04326023 | Cancer | PARP Inhibitors | - | University Hospital, Caen | |
| ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa | NCT06200558 | Prostate Cancer | 18 Years - | Hospital of Macerata | ||
| Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency | NCT06120972 | Ovarian Cancer | Olaparib tablet | 18 Years - | University of Pittsburgh | |
| Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency | NCT06120972 | Ovarian Cancer | Olaparib tablet | 18 Years - | University of Pittsburgh | |
| ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa | NCT06200558 | Prostate Cancer | 18 Years - | Hospital of Macerata | ||
| First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | NCT06063070 | Ovarian Cancer High Grade Sero... High Grade Endo... Primary Periton... Fallopian-tube ... | Fluzoparib Caps... Bevacizumab | 18 Years - | Sun Yat-sen University | |
| The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer | NCT04582552 | Ovarian Cancer Clinical Marker PARP Inhibitor | PARP inhibitors | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats | NCT01078662 | Ovarian Breast Prostate Pancreatic Advanced Tumour... | olaparib | 18 Years - 130 Years | AstraZeneca | |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | NCT06161272 | Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ... | Fluzoparib Fluzoparib+Apat... | 18 Years - 75 Years | Guangxi Medical University | |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors | NCT01618136 | Malignant Solid... Ovarian Cancer Triple Negative... Advanced Melano... B-cell Malignan... | E7449 alone E7449 plus TMZ E7449 plus carb... | 18 Years - | Eisai Inc. | |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors | NCT01618136 | Malignant Solid... Ovarian Cancer Triple Negative... Advanced Melano... B-cell Malignan... | E7449 alone E7449 plus TMZ E7449 plus carb... | 18 Years - | Eisai Inc. | |
| Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors | NCT04675320 | Ovarian Cancer | blood samples | 18 Years - | Centre Georges Francois Leclerc | |
| Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer | NCT01081951 | Ovarian Cancer | olaparib paclitaxel carboplatin paclitaxel Drug: carboplat... | 18 Years - 125 Years | AstraZeneca | |
| First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | NCT06063070 | Ovarian Cancer High Grade Sero... High Grade Endo... Primary Periton... Fallopian-tube ... | Fluzoparib Caps... Bevacizumab | 18 Years - | Sun Yat-sen University | |
| Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats | NCT01078662 | Ovarian Breast Prostate Pancreatic Advanced Tumour... | olaparib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
